Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

265.26 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
ResMed Secures Significant Victory in Patent Fight Against New York University
From ResMed Inc.
Via GlobeNewswire
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
From ResMed Inc.
Via GlobeNewswire
Why NYSE:RMD qualifies as a good dividend investing stock.
Is RESMED INC (NYSE:RMD) a Good Fit for Dividend Investing? 
Via Chartmill
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump. 
Via Benzinga
Why the dividend investor may take a look at NYSE:RMD.
Analyzing RESMED INC (NYSE:RMD)'s Dividend Potential. 
Via Chartmill
Is NYSE:RMD a Good Fit for Dividend Investing?
Analyzing RESMED INC (NYSE:RMD)'s Dividend Potential. 
Via Chartmill
ResMed Adopts New Operating Model to Accelerate Long-term Growth
From ResMed Inc.
Via GlobeNewswire
2 Monster Stocks to Buy Without Any Hesitation
Down 33% and 44%, these two stocks look too good to pass up today. 
Via The Motley Fool
How Sleep Device Player ResMed Is Gaining Philips' Market Share In Flow Generator Market - Analysts Weigh In
Needham analyst Mike Matson reiterated a Buy rating on ResMed Inc. (NYSE: RMD)  
Via Benzinga
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story. 
Via Investor's Business Daily
Expert Ratings for ResMed
 
Via Benzinga
What 6 Analyst Ratings Have To Say About ResMed
 
Via Benzinga
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
Earnings Scheduled For October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion. 
Via Benzinga
3 Stocks to Buy From the ‘Buy the Dip’ ETF
It’s a lot harder than it looks to buy the dip. Using artificial intelligence to do this makes these three stocks a buy. 
Via InvestorPlace
Topics Artificial Intelligence
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023
 
Via Benzinga
Exxon Mobil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Thursday
Cantor Fitzgerald cut Hyliion Holdings Corp. (NYSE: HYLN) price target from $2 to $1. Cantor Fitzgerald analyst Andres Sheppard downgraded the stock from Neutral to Underweight. Hyliion shares fell... 
Via Benzinga
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023
From ResMed Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
3 Top Growth Stock Picks Trading at a Massive Bargain
These growth stock picks are trading at bargain prices and are well-positioned to rebound and deliver substantial gains in the coming months. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
Is It Time to Buy the S&P 500's 3 Worst-Performing August Stocks?
The S&P 500 had a rare decline last month. 
Via The Motley Fool
Topics Stocks
Sleep Device Player ResMed's Potential Obstacles: Analyst Weighs Obesity Drugs & Philips' Re-Entry
Needham upgraded ResMed Inc (NYSE: RMD) from a Hold to Buy rating with a price target of $180 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
 
Via Benzinga
ResMed Announces Participation in Upcoming Conferences
From ResMed Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023
 
Via Benzinga
American Express To Rally Over 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo raised the price target for Equity Residential (NYSE: EQR) from $62 to $69. Wells Fargo analyst James Feldman upgraded the stock from Equal-Weight to Overweight. Equity Residential shares... 
Via Benzinga
3 Reasons ResMed's CEO Isn't Worried About Ozempic or Wegovy
Mick Farrell might be kidding himself about the degree to which the popular weight-loss drugs will impact his company. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.